Sellas Life Sciences Group Inc (SLS) financials
Sellas Life Sciences Group revenue and earnings by year
Sellas Life Sciences Group's revenue was $1.00 million in the fiscal year to December 31, 2022, down 86.8% from the year before. Net income was -$41.3 million, -4130.1% of revenue.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 3 fiscal years
| Fiscal year to | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|
| Revenue | 1 | 8 | 2 |
| Revenue growth | -86.8% | 300.0% | — |
| Gross profit | 1 | 7 | — |
| Gross margin | 90.0% | 97.4% | — |
| Operating income | -42 | -25 | -17 |
| Operating margin | -4195.0% | -332.8% | -893.8% |
| Net income | -41 | -21 | -17 |
| Net margin | -4130.1% | -272.4% | -881.9% |
| Diluted EPS | -$2.13 | -$1.34 | -$2.13 |
| Free cash flow | -24 | -26 | -10 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open SLS in Markets.
See also: SLS returns
No forecast, no recommendation. This page describes Sellas Life Sciences Group Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.